EPOR and prostate neoplasm: All samples expressed detectable levels of EPOR and ERBB2. IGF1R mRNA expression was also common with 4/7 (57%) normal prostate samples, 25/30 (83%) prostate tumors, and 7/11 (64%) benign prostatic hypertrophy samples expressing detectable levels.